Stocks · Health care · Pharmaceutical Preparations

Rapport Therapeutics, Inc.

RAPP Clue Score46

United States Fiscal year ends December CIK 0002012593 Results filed 4 Nov 2026

Add to watchlist

What the insiders did Net buying

By person

14 insiders · 128 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Third Rock Ventures V, L.P. entity

Director

—

$34.39M (5) scheduled

−$34.39M

9,647,532

20.11%

$202.60M

+521.2%

James Healy

Director

$30.94M (21)

—

+$30.94M

2,914,739

6.08%

$61.21M

—

Abraham Ceesay

Chief Executive Officer

—

$8.29M (44) scheduled

−$8.29M

573,222

1.19%

$12.04M

−29.3%

Krishnaswamy Yeleswaram

Chief Development Officer

—

$4.46M (11) scheduled

−$4.46M

195,862

0.4082%

$4.11M

−32.7%

David Bredt

Chief Scientific Officer

—

$2.16M (21) scheduled

−$2.16M

393,075

0.8193%

$8.25M

−23.5%

Steven M Paul

Director

$2.00M (3)

—

+$2.00M

596,688

1.24%

$12.53M

+14.9%

Cheryl Gault

Chief Operating Officer

—

$1.43M (11) scheduled

−$1.43M

139,914

0.2916%

$2.94M

−11.4%

Reid M Huber

Director

$499.37K (1)

—

+$499.37K

20,400

0.0425%

$428.40K

—

John Maraganore

Director

$248.89K (2)

—

+$248.89K

9,411

0.0196%

$197.63K

—

Troy A. Ignelzi

Chief Financial Officer

$244.54K (3)

—

+$244.54K

15,500

0.0323%

$325.50K

—

Wendy B. Young

Director

$240.34K (3)

—

+$240.34K

13,289

0.0277%

$279.07K

—

Paul M Silva

Director

$99.64K (1)

—

+$99.64K

3,680

0.0077%

$77.28K

—

Ramiro Sanchez

Director

$98.48K (1)

—

+$98.48K

3,600

0.0075%

$75.60K

—

ARCH Venture Partners XII, LLC entity

10% owner

—

—

—

3,728,738

7.77%

$78.30M

—